Polycystic Ovary Syndrome (PCOS) has been renamed Polyendocrine Metabolic Ovary Syndrome (PMOS) in a historic shift based on global consensus.
The PCOS to PMOS shift follows a 14-year global collaboration led by Monash University and the AE-PCOS Society, involving 50 organizations and 22,000 respondents.
The new name, PMOS, published in The Lancet, aims to correct the medical inaccuracy of full-term cysts and understand the condition that affects more than 170 million women through intersectionality of its metabolic, hormonal and mental health impacts.
The name rebrand also aims to educate people that PCOS is not just about cysts in the ovaries or reproductive systems, but a complex endocrine and metabolic condition that can affect the entire body.
Because PCOS in traditional terms is just a hormonal problem, and not the condition with a systemic endocrine disorder.
The new name avoids certain reproductive terms that carry a cultural stigma in various parts of the world.
Professor Helena Teede, director of the Monash Center for Health Research & Implementation and endocrinologist at Monash Health, Melbourne, Australia, who led the name change process, said: “What we now know is that there has actually been no increase in abnormal ovarian cysts, and that the various features of the condition have often gone unappreciated.”
“It was heartbreaking to see the delayed diagnosis, limited awareness and inadequate care provided to those affected by this neglected condition.”
Implementation timeline
According to the organization, a three-year education and awareness campaign is currently underway. The name will be fully integrated into the 2028 International Guideline update.
Why is this shift important to millions of women?
For millions of women around the world, this distinction is important because changes in language and understanding can shape medical treatments, research priorities, self-understanding, public understanding and mental insight.
Because for years, people struggling with PMOS have faced many challenges related to delayed diagnosis, shame around symptoms, assumptions about fertility, and mental health issues that were not fully recognized.
Professor Teede added: “The agreed principles of the new name include patient benefit, scientific accuracy, ease of communication, avoidance of stigma, cultural appropriateness and associated implementation.”
Medical experts and advocates believe the name change will change the way we view the symptoms and treatment. The shift is expected to lead to earlier diagnoses and more thorough treatment.
According to experts, PMOS will go beyond the narrow reproductive framework and promote accurate diagnosis, reduce cultural barriers and stigma, support holistic care and expand research from the hormonal to the metabolic domain.
According to Melanie Cree, MD, PhD, pediatric endocrinologist at the University of Colorado Anschutz, “What makes this effort particularly powerful is that it lays the foundation for meaningful change, from medical education to clinical guidelines to public awareness and ultimately better patient care outcomes.”
In short, PMOS is not just a name change; it is a historic shift toward its recognition as real, multifaceted, and systematic, worthy of comprehensive care and investigation
